KR102783770B1 - 디시클로플라틴을 함유하는 복합 산물, 이의 제조 및 용도 - Google Patents
디시클로플라틴을 함유하는 복합 산물, 이의 제조 및 용도 Download PDFInfo
- Publication number
- KR102783770B1 KR102783770B1 KR1020207015518A KR20207015518A KR102783770B1 KR 102783770 B1 KR102783770 B1 KR 102783770B1 KR 1020207015518 A KR1020207015518 A KR 1020207015518A KR 20207015518 A KR20207015518 A KR 20207015518A KR 102783770 B1 KR102783770 B1 KR 102783770B1
- Authority
- KR
- South Korea
- Prior art keywords
- dicycloplatin
- patient
- cancer
- delete delete
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0013—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
- C07C65/10—Salicylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711164023 | 2017-11-21 | ||
| CN201711164023.6 | 2017-11-21 | ||
| PCT/CN2018/116213 WO2019101040A1 (zh) | 2017-11-21 | 2018-11-19 | 含有双环铂的组合产品、其制备方法及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200090170A KR20200090170A (ko) | 2020-07-28 |
| KR102783770B1 true KR102783770B1 (ko) | 2025-03-18 |
Family
ID=66630485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207015518A Active KR102783770B1 (ko) | 2017-11-21 | 2018-11-19 | 디시클로플라틴을 함유하는 복합 산물, 이의 제조 및 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200361973A1 (https=) |
| EP (1) | EP3714881A4 (https=) |
| JP (1) | JP7356438B2 (https=) |
| KR (1) | KR102783770B1 (https=) |
| CN (1) | CN111356454B (https=) |
| AU (1) | AU2018372753B2 (https=) |
| CA (1) | CA3082295A1 (https=) |
| IL (1) | IL274785A (https=) |
| MX (1) | MX2020005310A (https=) |
| WO (1) | WO2019101040A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3008699T3 (en) | 2017-11-17 | 2025-03-24 | Renovion Inc | Stable ascorbic acid compositions and methods of using the same |
| IL313997A (en) | 2022-01-04 | 2024-08-01 | Renovion Inc | Aqueous solution including glutathione salt |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016166040A1 (en) | 2015-04-12 | 2016-10-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
| WO2016172393A1 (en) | 2015-04-22 | 2016-10-27 | Syn-Nat Products Enterprise LLC | Co-crystal composition and its pharmaceutical use |
| WO2016187191A1 (en) | 2015-05-18 | 2016-11-24 | Medoc Pharmaceutical Co., Ltd. | A pharmaceutical co-crystal and use thereof |
| WO2016205782A1 (en) * | 2015-06-19 | 2016-12-22 | Syn-Nat Products Enterprise LLC | Composition containing carboplatin and use |
| WO2017060661A1 (en) * | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922689A (en) | 1995-09-11 | 1999-07-13 | Unitech Pharmaceuticals, Inc. | Cisplatin analogs for cancer treatment |
| US6896899B2 (en) * | 1996-12-31 | 2005-05-24 | Antioxidant Pharmaceuticals Corp. | Pharmaceutical preparations of glutathione and methods of administration thereof |
| US6297245B1 (en) | 1998-08-04 | 2001-10-02 | Unitech Pharmaceuticals | Cisplatin and folic acid administered to treat breast cancer |
| CN1121380C (zh) * | 2000-03-03 | 2003-09-17 | 北京兴大豪斯科技有限公司 | 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物 |
| AU2004270655B2 (en) | 2003-08-13 | 2011-03-24 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| ITMI20070770A1 (it) * | 2007-04-16 | 2008-10-17 | Brane Discovery S R L | Impiego di dimiracetam nel trattamento del dolore cronico |
| US20110206638A1 (en) * | 2010-01-20 | 2011-08-25 | The Regents Of The University Of California | Compositions and methods for reducing the mutation rate of viruses |
| CN104127402B (zh) * | 2014-08-15 | 2019-08-30 | 北京默加农生物技术发展有限公司 | 双环铂在制备抗病毒药物和抗菌药物中的应用 |
| EP3280408B1 (en) * | 2015-04-10 | 2019-10-23 | Syn-Nat Products Enterprise LLC | Process for the preparation of dicycloplatin |
| US10428099B2 (en) * | 2015-06-25 | 2019-10-01 | Syn-Nat Products Enterprise LLC | Pharmaceutical co-crystal composition and use thereof |
-
2018
- 2018-11-19 MX MX2020005310A patent/MX2020005310A/es unknown
- 2018-11-19 CN CN201880074343.9A patent/CN111356454B/zh active Active
- 2018-11-19 WO PCT/CN2018/116213 patent/WO2019101040A1/zh not_active Ceased
- 2018-11-19 JP JP2020545427A patent/JP7356438B2/ja active Active
- 2018-11-19 US US16/765,024 patent/US20200361973A1/en active Pending
- 2018-11-19 KR KR1020207015518A patent/KR102783770B1/ko active Active
- 2018-11-19 EP EP18880461.1A patent/EP3714881A4/en active Pending
- 2018-11-19 AU AU2018372753A patent/AU2018372753B2/en active Active
- 2018-11-19 CA CA3082295A patent/CA3082295A1/en active Pending
-
2020
- 2020-05-20 IL IL274785A patent/IL274785A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016166040A1 (en) | 2015-04-12 | 2016-10-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
| WO2016172393A1 (en) | 2015-04-22 | 2016-10-27 | Syn-Nat Products Enterprise LLC | Co-crystal composition and its pharmaceutical use |
| WO2016187191A1 (en) | 2015-05-18 | 2016-11-24 | Medoc Pharmaceutical Co., Ltd. | A pharmaceutical co-crystal and use thereof |
| WO2016205782A1 (en) * | 2015-06-19 | 2016-12-22 | Syn-Nat Products Enterprise LLC | Composition containing carboplatin and use |
| WO2017060661A1 (en) * | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021504452A (ja) | 2021-02-15 |
| JP7356438B2 (ja) | 2023-10-04 |
| RU2020116704A (ru) | 2021-12-22 |
| CN111356454B (zh) | 2023-04-07 |
| IL274785A (en) | 2020-07-30 |
| WO2019101040A1 (zh) | 2019-05-31 |
| EP3714881A1 (en) | 2020-09-30 |
| AU2018372753B2 (en) | 2024-03-21 |
| CN111356454A (zh) | 2020-06-30 |
| AU2018372753A1 (en) | 2020-05-28 |
| CA3082295A1 (en) | 2019-05-31 |
| US20200361973A1 (en) | 2020-11-19 |
| EP3714881A4 (en) | 2021-09-01 |
| KR20200090170A (ko) | 2020-07-28 |
| MX2020005310A (es) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017162108A1 (zh) | 一种柱芳烃类复合物、其制备方法、药物组合物和用途 | |
| Wang et al. | Cordycepin, a natural antineoplastic agent, induces apoptosis of breast cancer cells via caspase-dependent pathways | |
| US8691870B2 (en) | Use of isothiocyanates for treating cancer | |
| KR20210103426A (ko) | 담즙산 또는 이의 유도체, 바이구아나이드 계열 화합물 및 항바이러스제 중 2종 이상을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 | |
| CN106822905A (zh) | 含Survivin抑制剂和IRE1抑制剂的药物及用途 | |
| CN103356515B (zh) | 一种大黄素类蒽醌衍生物在制备抗肝癌药物中的应用 | |
| CN102552908B (zh) | 含青蒿素及青蒿素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
| CN102698275A (zh) | 一类杨梅素类似黄酮醇类化合物在制备抗肿瘤药物中的用途 | |
| Rautray et al. | Anticancer activity of Adiantum capillus veneris and Pteris quadriureta L. in human breast cancer cell lines | |
| KR102783770B1 (ko) | 디시클로플라틴을 함유하는 복합 산물, 이의 제조 및 용도 | |
| CN102441168B (zh) | 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用 | |
| EP3043809B1 (en) | Filipendula vulgaris extract and uses thereof | |
| CN101940569B (zh) | 含有索拉非尼和青蒿素及青蒿素类衍生物的药物组合物及其在制备治疗癌症的药物中的应用 | |
| CN102688493B (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用 | |
| CN102697768A (zh) | 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途 | |
| CN108295085B (zh) | 原薯蓣皂苷在制备抗耐药性骨肉瘤药物中的应用 | |
| JP2016521689A (ja) | シナラ属種の抽出物及びその使用 | |
| RU2784809C2 (ru) | Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения | |
| CN102688489A (zh) | 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
| JP2018501304A (ja) | シナラ・スコリムスの滴定抽出物及びそれらの使用 | |
| US11142539B2 (en) | Phosphinogold(I) complexes and methods of treating cancer | |
| JP6820567B2 (ja) | 癌治療剤 | |
| CN102688490B (zh) | 含有吴茱萸碱及吴茱萸碱类衍生物和Bc1-2抑制剂的药物组合物及其应用 | |
| HK40029757A (en) | Combination product comprising dicycloplatin and preparation method and use thereof | |
| HK40029757B (en) | Combination product comprising dicycloplatin and preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200529 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211110 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240401 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250102 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250314 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250314 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |